Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2007

01-08-2007 | Article

Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea

Authors: S.-H. Choi, J. E. Lee, S. J. Park, M.-N. Kim, E. J. Choo, Y. G. Kwak, J.-Y. Jeong, J. H. Woo, N. J. Kim, Y. S. Kim

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2007

Login to get access

Abstract

We examined the prevalence and characteristics of extended-spectrum β-lactamase (ESBL)-producing clinical isolates among Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii, and evaluated screening criteria, clinical characteristics and outcomes of infections caused by ESBL-producing organisms. Between January and June 2005, a total of 493 nonduplicate consecutive isolates were collected at Asan Medical Center, a 2,300-bed tertiary hospital in Seoul, Republic of Korea. Fifty isolates (10.1%) were positive for phenotypical ESBL-test. The positive rate of phenotypical ESBL-test in Enterobacter spp., S. marcescens, C. freundii, and M. morgannii was 12.8%, 12.4%, 4.9%, and 0% respectively. SHV-12 (18 isolates), CTX-M-9 (17 isolates), and TEM-52 (five isolates) were the most prevalent ESBL types. The ESBL in 17 strains could not be identified. As an ESBL screening criterion, the cefepime MIC ≥1 μg/ml had the highest sensitivity (0.84) and specificity (0.87). Half of the ESBL-producing isolates (25/50) were judged as pathogens. Cholangitis (ten cases), and pneumonia (six cases) were the most common infections. The overall mortality was 12.0%.
Literature
1.
go back to reference Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585–590PubMed Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585–590PubMed
2.
go back to reference Ho PL, Shek RH, Chow KH, Duan RS, Mak GC, Lai EL, Yam WC, Tsang KW, Lai WM (2005) Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000–2002. J Antimicrob Chemother 55:326–332PubMedCrossRef Ho PL, Shek RH, Chow KH, Duan RS, Mak GC, Lai EL, Yam WC, Tsang KW, Lai WM (2005) Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000–2002. J Antimicrob Chemother 55:326–332PubMedCrossRef
3.
go back to reference Kim J, Lim YM (2005) Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol 43:2452–2455PubMedCrossRef Kim J, Lim YM (2005) Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol 43:2452–2455PubMedCrossRef
4.
go back to reference Pai H, Hong JY, Byeon JH, Kim YK, Lee HJ (2004) High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 48:3159–3161PubMedCrossRef Pai H, Hong JY, Byeon JH, Kim YK, Lee HJ (2004) High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 48:3159–3161PubMedCrossRef
5.
go back to reference Park YJ, Park SY, Oh EJ, Park JJ, Lee KY, Woo GJ, Lee K (2005) Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51:265–269PubMedCrossRef Park YJ, Park SY, Oh EJ, Park JJ, Lee KY, Woo GJ, Lee K (2005) Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51:265–269PubMedCrossRef
6.
go back to reference Clinical and Laboratory Standards Institute (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6: 6th edition. CLSI, Villanova, PA Clinical and Laboratory Standards Institute (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6: 6th edition. CLSI, Villanova, PA
7.
go back to reference Jacoby GA, Han P (1996) Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 34:908–911PubMed Jacoby GA, Han P (1996) Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 34:908–911PubMed
8.
go back to reference Sanders CC, Sanders WE Jr, Goering RV (1982) In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother 21:968–975PubMed Sanders CC, Sanders WE Jr, Goering RV (1982) In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother 21:968–975PubMed
9.
go back to reference Sanders CC, Sanders WE Jr (1979) Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother 15:792–797PubMed Sanders CC, Sanders WE Jr (1979) Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother 15:792–797PubMed
10.
go back to reference Schwaber MJ, Raney PM, Rasheed JK, Biddle JW, Williams P, McGowan JE Jr, Tenover FC (2004) Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobactericeae. J Clin Micriobiol 42:294–298CrossRef Schwaber MJ, Raney PM, Rasheed JK, Biddle JW, Williams P, McGowan JE Jr, Tenover FC (2004) Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobactericeae. J Clin Micriobiol 42:294–298CrossRef
11.
go back to reference Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A; Cefepime Study Group (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442–3447PubMedCrossRef Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A; Cefepime Study Group (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442–3447PubMedCrossRef
12.
go back to reference Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, Van Herck K, Jorens PG, Demey HE, Ieven M, Bossaert L, Goossens H (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12:56–62PubMedCrossRef Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, Van Herck K, Jorens PG, Demey HE, Ieven M, Bossaert L, Goossens H (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12:56–62PubMedCrossRef
Metadata
Title
Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea
Authors
S.-H. Choi
J. E. Lee
S. J. Park
M.-N. Kim
E. J. Choo
Y. G. Kwak
J.-Y. Jeong
J. H. Woo
N. J. Kim
Y. S. Kim
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0308-2

Other articles of this Issue 8/2007

European Journal of Clinical Microbiology & Infectious Diseases 8/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine